Faheem Hasnain

Faheem Hasnain is the founder of Gossamer Bio, Inc., founded in 2015, serving as Chairman, President & Chief Executive Officer.
Current jobs include Chairman at Aspen Neuroscience, Inc. since 2020; Chairman at SENTÉ Labs since 2008; Chairman at Sling Therapeutics, Inc. since 2021; Lead Independent Director at Kura Oncology, Inc. since 2020; Member-Overseers Board at The Scripps Research Institute since 2018; and Venture Advisor at Vertex Ventures HC since 2020.
Former jobs include President, Chief Executive Officer & Director at Abbott Biotherapeutics Corp.
from 2008 to 2010; President, Chief Executive Officer & Director at Receptos LLC from 2010 to 2015; President, Chief Executive Officer & Director at PDL BioPharma, Inc. in 2008; Chairman at Ambit Biosciences Corp.
from 2010 to 2014; Chairman at Tocagen, Inc. from 2014 to 2020; Chairman at Mirati Therapeutics, Inc. from 2019 to 2024; Chairman at Vital Therapies, Inc. from 2017 to 2019; Chairman at Panacea Acquisition Corp.
from 2020 to 2021; Chairman at Senté, Inc.; Director at Tercica, Inc. in 2008; Independent Director at Somaxon Pharmaceuticals, Inc. from 2010 to 2013; Independent Director at Aragon Pharmaceuticals, Inc. from 2012 to 2013; Director at Seragon Pharmaceuticals, Inc. from 2013 to 2015; Director at Pernix Sleep, Inc.; President-Oncology Therapeutics Network at Bristol Myers Squibb Co. from 2002 to 2004; Executive Vice President-Oncology at Biogen, Inc. from 2004 to 2008; Vice President-Global eBusiness at GSK Plc from 1988 to 2002; EVP-Oncology & Rheumatology Strategic Business at Biogen Idec, Inc. (North Carolina) from 2004 to 2008; and President at Oncology Therapeutics Network Corp.
from 2002 to 2004.
Education includes an undergraduate degree from the University of Windsor, conferred in 1983.